Rare kidney cancer resists immune therapies due to lack of active T-cells

Cancer-fighting T-cells, the immune system’s primary enforcers, are scarce in the rare kidney cancer called chromophobe renal cell carcinoma (ChRCC) and those that are present are indifferent to the tumor threat and traditional immune therapies, revealing the need for new targets and treatments.

This article was originally published on MedicalXpress.com

You may also be interested in:

Read More:

Lawyers Lookup